Compare Biogen Inc (BIIB) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Wayfair Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Wayfair Inc trades at $102.74 (market cap $14.14B). The key difference: Biogen Inc is far larger — about 2.1× Wayfair Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Wayfair Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | W | |
|---|---|---|
Market Cap | $30.13B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $119.05 |
52-Week Low | $128.93 | $57.40 |
Enterprise Value | $37.20B | $16.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Wayfair (W) trades at $102.79, down 0.52% on the day, with a bullish technical signal supported by a golden cross and recent 30% post-earnings rally. Q2 2026 EPS of $0.95 beat estimates, driven by 7.5% revenue growth and strong U.S. demand, though net margins remain negative. Analyst consensus is bullish with a $122 price target, citing market share gains and margin expansion prospects.
Outlook: Growth momentum and positive sentiment offer upside potential, but risks include persistent losses, high debt-to-asset ratio (95.11% in 2025), and volatile consumer spending. Investors should weigh robust U.S. performance against international weakness and profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
